Pulsed proton beams aim to tame tough pancreatic tumors
NCT ID NCT07269626
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a new radiation technique called PULSAR, which delivers short, powerful proton beam pulses every few weeks, adapted to tumor changes. It is for people with locally advanced or limited metastatic pancreatic cancer who have already had some chemotherapy. The goal is to improve local control and survival while reducing damage to nearby organs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Proton beam radiation delivered in personalized ultra-fractionated pulses (PULSAR)
What this could lead to
If successful, this approach could improve local tumor control and survival for patients with advanced pancreatic cancer while reducing side effects from radiation.
What could go wrong
This is a small, early-phase (phase II) trial with only 47 participants, so results may not apply broadly. The combination therapy may still cause toxicity or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Select Province/State, 06351, South Korea
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact